On April 28, 2025, the Eighth Meeting of Health Ministers of Member States of the Shanghai Cooperation Organization (hereinafter referred to as the "SCO") was held in Xi'an. Under the SCO national cooperation mechanism, Chinese vaccine companies represented by Sinovac have jointly built a diversified cooperation system covering R&D, supply and industrialization with partners from multiple countries, to help the development of SCO national public health.

At present, Sinovac has established close cooperative relations with 17 SCO countries, and has supplied more than 33 million doses of conventional vaccines such as hepatitis A vaccine, influenza vaccine, chickenpox vaccine, etc. to member countries outside China. Among them, Sinovac hepatitis A vaccine is the first choice for many SCO national immunization programs. It has supplied more than 10 million doses to SCO member countries such as Uzbekistan, Kazakhstan, India, and Pakistan to effectively protect the health of local people. Taking Uzbekistan as an example, Sinovac's hepatitis A vaccine has a share of more than 95% of the local private market, with a supply of 500,000 doses in 2024, covering nearly 70% of new school children.

As the only chickenpox vaccine in China that has been pre-certified by the World Health Organization (WHO), Sinovac chickenpox vaccine was first supplied to Belarus at the end of 2023, promptly alleviating the local vaccine shortage. Its influenza vaccine successfully entered the Pakistani market in 2024 and quickly became the mainstream influenza vaccine brand in the local area. Previously, in the face of severe floods in Pakistan, Sinovac also donated 100,000 doses of hepatitis A vaccine to the country, reflecting the company's sense of social responsibility and international humanitarian spirit.

In addition to commercial cooperation, Sinovac and SCO dialogue partner countries are actively carrying out diversified cooperation such as industrialization. Sinovac jointly established a KeyVac vaccine factory with local Turkey partners, which put into production fills the gap in Türkiye's domestic hepatitis A vaccine and other fields. At the same time, an automated vaccine cold storage with a construction area of ​​2,800 square meters was built in Egypt. It has now become the largest vaccine storage center in Africa, greatly improving the local vaccine cold chain logistics capacity.

As one of China's first vaccine manufacturers to pass the World Health Organization pre-certified, Sinovac has 4 vaccines that have passed the WHO pre-certification or emergency use certification, and have supplied more than 1.2 billion doses of vaccines in 62 countries. Through the cooperation model of technology output and localized production, the company has signed a vaccine production authorization agreement with 12 countries jointly built the "Belt and Road" and promoted localized production in some countries, and continuously improved the accessibility and affordability of vaccines.

April 28 also marks the 24th anniversary of the establishment of Sinovac. Since its establishment, Sinovac has always adhered to the mission of "providing vaccines for mankind with eliminating diseases", and has successively developed 12 vaccines, which are widely used in many countries and regions around the world, covering the immune needs of all ages from children to adults. In the future, Sinovac will continue to be innovatively driven and work with partners from all countries to contribute greater strength to the global public health cause.

[Editor in charge: Li Chen]